Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCG | P01275 | 15/20 | 0.40 |
| ▸ | GCGR | P47871 | 2/20 | 0.36 |
| ▸ | GLP1R | P43220 | 1/20 | 0.36 |
| ▸ | GIPR | P48546 | 1/20 | 0.36 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.36 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.36 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.36 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.36 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.36 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.36 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.36 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.36 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6751723 | 0.93 | GCG (0.39) | GCGGCGRGLP1RGIPRADCY6 | |
| SCHEMBL2651899 | 0.88 | GCG (0.44) | GCGGCGRGLP1RGIPRADCY6 | |
| SCHEMBL6751722 | 0.87 | GCG (0.38) | GCGGCGRGLP1RGIPR | |
| SCHEMBL6751919 | 0.85 | MCHR1 (0.44) | GCGGCGRADCY6ADCY3ADCY9 | |
| SCHEMBL2651127 | 0.82 | L3MBTL1 (0.41) | GCGGCGRGLP1RGIPR | |
| SCHEMBL2659969 | 0.81 | GCGR (0.54) | GCGRGLP1RGIPRADCY6ADCY3 | |
| SCHEMBL6748286 | 0.79 | MCHR1 (0.42) | GCGGCGRADCY6ADCY3ADCY9 | |
| SCHEMBL2650711 | 0.79 | ALDH1A1 (0.43) | GCG | |
| SCHEMBL6751739 | 0.79 | GCGR (0.47) | GCGRGLP1RGIPRADCY6ADCY3 | |
| SCHEMBL2650935 | 0.79 | GCGR (0.53) | GCGGCGRGLP1RGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127560-A1 | Glucagon antagonists/inverse agonists | MADSEN PETER (DK) | 2004-07-01 | — | — | US | claimed |
| US-6706744-B2 | HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DK) | 2004-03-16 | — | — | US | claimed |
| US-20030065031-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-04-03 | — | — | US | claimed |
| WO-2002040444-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-05-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127560-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCG 6/4885GCGR 3/4885GLP1R 1/4885 |
| US-20030065031-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCG 6/4885GCGR 3/4885GLP1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.